Document Detail


Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.
MedLine Citation:
PMID:  23314414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum. Compared with postpartum, geometric mean amprenavir (APV, FPVs active metabolite) area under the plasma concentration-time curves were 35% lower in the second trimester and 25% lower in the third trimester. Maternal APV concentrations were 9- to 15-fold above the mean APV protein-adjusted 50% inhibitory concentration for wild-type HIV. Median ratio of cord blood/maternal APV levels was 0.27, and all infants were HIV negative. FPV/ritonavir during pregnancy was well tolerated and led to virologic suppression.
Authors:
Michelle S Cespedes; Delivette Castor; Susan L Ford; Doreen Lee; Yu Lou; Gary E Pakes; Judith A Aberg
Related Documents :
9418694 - Tubal patency and fertility outcome after expectant management of ectopic pregnancy.
6078894 - Postpartum sterilization.
3700724 - Timing and positioning of reopening of the occluded spinal neurocele in the chick embryo.
11471924 - Laparoscopic fertility-promoting procedures of the fallopian tube and the uterus.
3701834 - Sequential studies of nk cell activity in human pregnancy.
7060764 - Pregnancy outcome following microsurgical fimbrioplasty.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  62     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2013-10-18     Revised Date:  2014-04-16    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  550-4     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Area Under Curve
Carbamates / administration & dosage,  pharmacokinetics*
Disease Transmission, Infectious / prevention & control
Female
Fetal Blood
HIV / isolation & purification
HIV Infections / drug therapy,  metabolism*,  prevention & control,  virology
HIV Protease Inhibitors / administration & dosage,  pharmacokinetics*
Humans
Infant, Newborn
Organophosphates / administration & dosage,  pharmacokinetics*
Postpartum Period / blood,  metabolism
Pregnancy
Pregnancy Complications, Infectious / blood,  drug therapy*,  metabolism*,  virology
Ritonavir / administration & dosage,  pharmacokinetics*
Sulfonamides / administration & dosage,  pharmacokinetics*
Young Adult
Grant Support
ID/Acronym/Agency:
1UL1RR029893/RR/NCRR NIH HHS; AI069532/AI/NIAID NIH HHS; U01 AI068636/AI/NIAID NIH HHS; U01 AI069532/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Carbamates; 0/HIV Protease Inhibitors; 0/Organophosphates; 0/Sulfonamides; O3J8G9O825/Ritonavir; WOU1621EEG/fosamprenavir
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A randomized trial of Mogen clamp versus Plastibell for neonatal male circumcision in Botswana.
Next Document:  Prolonged decrease of CD4+ T lymphocytes in HIV-1 infected patients after radiotherapy for a solid t...